Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Supportive Care in Cancer
Erschienen in: Supportive Care in Cancer 3/2016

01.03.2016 | Review Article

Chemotherapy at end-of-life: an integration of oncology and palliative team

verfasst von: Wing-lok Chan, Ka-on Lam, Wai-kwan Siu, Kwok-keung Yuen

Erschienen in: Supportive Care in Cancer | Ausgabe 3/2016

Einloggen, um Zugang zu erhalten

Abstract

Palliative chemotherapy is increasingly used in cancer patients near end of life. With the development of newer anticancer agents which have less side effects and higher expected efficacy, the decision on palliative chemotherapy in patients near end of life is complex. This article illustrates how oncologist and palliative care physicians can work together effectively. This article also gives an overview about the risks of palliative chemotherapy near end of life, patients’ and physicians’ perspectives in choosing the aggressive treatment and describes what an oncologist should do when facing this challenging situation.
Literatur
1.
Emanuel EJ, Young-Xu Y, Levinsky NG, et al. (2003) Chemotherapy use among Medicare beneficiaries at the end of life. Ann Intern Med 138:639–643CrossRefPubMed
2.
Murillo Jr JR, Koeller J (2006) Chemotherapy given near the end of life by community oncologists for advanced non-small cell lung cancer. Oncologist 11:1095–1099
3.
4.
Earle CC, Neville BA, Landrum MB, Ayanian JZ, Block SD, Weeks JC (2004) Trends in the aggressiveness of cancer care near the end of life. J Clin Oncol 22(2):315–321CrossRefPubMed
5.
6.
Martoni AA, Tanneberger S, Mutri V (2007) Cancer chemotherapy near the end of life: the time has come to set guidelines for its appropriate use. Tumori 93(5):417–422PubMed
7.
8.
Connor SR, Pyenson B, Fitch K, Spence C, Iwasaki K (2007) Comparing hospice and nonhospice patient survival among patients who die within a three-year window. J Pain Symptom Manag 33(3):238–246CrossRef
9.
10.
11.
Lewin SN, Buttin BM, Powell MA, Gibb RK, Rader JS, Mutch DG, Herzog TJ (2005) Resource utilization for ovarian cancer patients at the end of life: how much is too much? Gynecol Oncol 99(2):261–266CrossRefPubMed
12.
Silvestri G, Pritchard R, Welch HG (1998) Preferences for chemotherapy in patients with advanced non-small cell lung cancer: descriptive study based on scripted interviews. BMJ 317(7161):771–775PubMedCentralCrossRefPubMed
13.
Agrawal M, Grady C, Fairclough DL, Meropol NJ, Maynard K, Emanuel EJ (2006) Patients’ decision-making process regarding participation in phase I oncology research. J Clin Oncol 24(27):4479–4484CrossRefPubMed
14.
Matsuyama R, Reddy S, Smith TJ (2006) Why do patients choose chemotherapy near the end of life? A review of the perspective of those facing death from cancer. J Clin Oncol 24(21):3490–3496CrossRefPubMed
15.
Koedoot CG, Oort FJ, de Haan RJ, Bakker PJ, de Graeff A, de Haes JC (2004) The content and amount of information given by medical oncologists when telling patients with advanced cancer what their treatment options are palliative chemotherapy and watchful-waiting. Eur J Cancer 40(2):225–235CrossRefPubMed
16.
Sullivan AM, Lakoma MD, Matsuyama RK, Rosenblatt L, Arnold RM, Block SD (2007) Diagnosing and discussing imminent death in the hospital: a secondary analysis of physician interviews. J Palliat Med 10(4):882–893CrossRefPubMed
17.
The AM, Hak T, Koëter G, van der Wal G (2001) Collusion in doctor-patient communication about imminent death: an ethnographic study. West J Med 174(4):247–253PubMedCentralCrossRefPubMed
18.
Mackillop WJ, Stewart WE, Ginsburg AD, Stewart SS (1988) Cancer patients’ perceptions of their disease and its treatment. Br J Cancer 58(3):355–358PubMedCentralCrossRefPubMed
19.
Amano K, Maeda I, Shimoyama S, Shinjo T, Shirayama H, Yamada T, Ono S, Yamamoto R, Yamamoto N, Shishido H, Shimizu M, Kawahara M, Aoki S, Demizu A, Goshima M, Goto K, Gyoda Y, Hashimoto K, Otomo S, Sekimoto M, Shibata T, Sugimoto Y, Morita T 2015 The accuracy of physicians’ clinical predictions of survival in patients with advanced cancer. J Pain Symptom Manage pii: S0885-3924(15)00161-X. doi: 10.​1016/​j.​jpainsymman.​2015.​03.​004
20.
Glare P, Virik K, Jones M, Hudson M, Eychmuller S, Simes J, Christakis N (2003) A systematic review of physicians’ survival predictions in terminally ill cancer patients. BMJ 327(7408):195–198PubMedCentralCrossRefPubMed
21.
Maltoni M, Caraceni A, Brunelli C, Broeckaert B, Christakis N, Eychmueller S, Glare P, Nabal M, Viganò A, Larkin P, De Conno F, Hanks G (2005) Kaasa S; Steering Committee of the European Association for Palliative Care. Prognostic factors in advanced cancer patients: evidence-based clinical recommendations—a study by the Steering Committee of the European Association for Palliative Care. J Clin Oncol 23(25):6240–6248CrossRefPubMed
22.
Maltoni M, Nanni O, Pirovano M, et al. (1999) Successful validation of the palliative prognostic score in terminally ill cancer patients. Italian multicenter study group on palliative care. J Pain Symptom Manag 17:240–247CrossRef
23.
Morita T, Tsunoda J, Inoue S, Chihara S (1999) The palliative prognostic index: a scoring system for survival prediction of terminally ill cancer patients. Support Care Cancer 7:128–133CrossRefPubMed
24.
Kim HS, Kim HJ, Kim SY, Kim TY, Lee KW, Baek SK, Kim TY, Ryu MH, Nam BH, Zang DY (2013) Second-line chemotherapy versus supportive cancer treatment in advanced gastric cancer: a meta-analysis. Ann Oncol 24(11):2850–2854. doi:10.​1093/​annonc/​mdt351 CrossRefPubMed
25.
Scarpi E, Maltoni M, Miceli R, Mariani L, Caraceni A, Amadori D, et al. (2011) Survival prediction for terminally ill cancer patients: revision of the palliative prognostic score with incorporation of delirium. Oncologist 16(12):1793–1799PubMedCentralCrossRefPubMed
26.
Baba M, Maeda I, Morita T, Hisanaga T, Ishihara T, Iwashita T, et al. (2015) Independent validation of the modified prognosis palliative care study predictor models in three palliative care settings. J Pain Symptom Manag 49(5):853–860. doi:10.​1016/​j.​jpainsymman.​2014.​10.​010 CrossRef
27.
Deyo RA, Cherkin DC, Ciol MA (1992) Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 45(6):613–619CrossRefPubMed
28.
Downing M, Lau F, Lesperance M, Karlson N, Shaw J, Kuziemsky C, et al. (2007) Meta-analysis of survival prediction with palliative performance scale. J Palliat Care 23(4):245–252 discussion 252-4PubMed
29.
30.
Chuang RB, Hu WY, Chiu TY, Chen CY (2004) Prediction of survival in terminal patients in Taiwan: constructing a prognostic scale. J Pain Symptom Manag 28:115–122CrossRef
31.
Metadaten
Titel
Chemotherapy at end-of-life: an integration of oncology and palliative team
verfasst von
Wing-lok Chan
Ka-on Lam
Wai-kwan Siu
Kwok-keung Yuen
Publikationsdatum
01.03.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
Supportive Care in Cancer / Ausgabe 3/2016
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-015-3031-z

Weitere Artikel der Ausgabe 3/2016

Supportive Care in Cancer 3/2016 Zur Ausgabe

Original Article

Illness perceptions among cancer survivors

Original Article

Poor chemotherapy-induced nausea and vomiting control in children receiving intermediate or high dose methotrexate

Original Article

Patients’ experiences and perspectives of multiple concurrent symptoms in advanced cancer: a semi-structured interview study

Original Article

Patient housing barriers to hematopoietic cell transplantation: results from a mixed-methods study of transplant center social workers

Original Article

Venous access: the patient experience

Original Article

Phase II evaluation of S-adenosyl-L-methionine (SAMe) for the treatment of hot flashes

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

23.04.2024 Medikamente in Schwangerschaft und Stillzeit Nachrichten

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise